Literature DB >> 33226198

Predictors of survival outcomes in sinonasal squamous cell carcinoma: an analysis of the National Cancer Database.

Nyssa Fox Farrell1, Jess C Mace1, Kara Y Detwiller1,2, Ryan Li3, Peter E Andersen3, Timothy L Smith1, Daniel R Clayburgh2,3, Mathew Geltzeiler1.   

Abstract

BACKGROUND: Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy that poses management challenges. Although surgery and chemoradiation therapy (CRT) remain therapeutic mainstays, induction chemotherapy (IC) has emerged as a useful adjunct with locally advanced disease. This study used the National Cancer Data Base (NCDB) to examine treatment outcomes for patients diagnosed with SNSCC.
METHODS: The NCDB (2004-2015) was queried for cases with SNSCC. Multivariate hazard regression modeling was used to identify significant predictors of 24-month and 60-month overall survival (OS) including treatment modality.
RESULTS: A total of 3516 patients with SNSCC met inclusion criteria, including 1750 patients (49.8%) treated with surgery ± adjuvant therapy, 1352 (38.5%) treated with definitive radiotherapy (RT) or CRT, 300 (8.5%) who underwent IC followed by definitive CRT, and 114 (3.2%) who received IC followed by surgery and adjuvant therapy. Hazard modeling for confirmed treatment modality significantly associated (p < 0.001) with OS after adjustment. Patients who received surgical intervention ± adjuvant therapy had lower 24-month and 60-month mortality risk compared to definitive RT or CRT (hazard ratio [HR] ≥ 1.97; p < 0.001) or IC followed by definitive CRT (HR ≥ 1.73; p < 0.001). Compared to primary surgery ± adjuvant therapy, patients undergoing IC then surgery had similar 24-month and 60-month OS (p ≥ 0.672) after adjustment.
CONCLUSION: Multimodality therapy, including surgical intervention, associates with improved OS after multifactorial adjustments. IC followed by surgery associated with improved OS compared to IC, followed by CRT and CRT alone. Study results highlight the utility of surgery toward optimizing OS in patients with SNSCC and demonstrates the potential utility of IC when primary surgical management is not preferred.
© 2020 ARS-AAOA, LLC.

Entities:  

Keywords:  carcinoma; drug therapy; neoplasms; outcome assessment (health care); radiotherapy; survival

Year:  2020        PMID: 33226198     DOI: 10.1002/alr.22737

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  3 in total

1.  Outcomes of Management of Sinonasal Malignancies at a Dedicated Cancer Institution: A Retrospective Study.

Authors:  Rahim Dhanani; Muhammad Faisal; Hamza Shahid; Kashif Iqbal Malik; Arif Jamshed; Raza Hussain
Journal:  Ann Maxillofac Surg       Date:  2021-07-24

2.  Treatment Outcomes of Maxillary Sinus Squamous Cell Carcinoma at a Dedicated Cancer Institute: A Retrospective Study.

Authors:  Ahmed A Keerio; Muhammad U Qayyum; Alina Kashif; Rahim Dhanani; Asma Rashid; Muhammad Faisal; Raza Hussain; Arif Jamshed
Journal:  Cureus       Date:  2022-06-03

Review 3.  EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.

Authors:  Laura Pacini; Virginia N Cabal; Mario A Hermsen; Paul H Huang
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.